Results 191 to 200 of about 601,448 (407)

Roadmap to Nanomedical Applications: Nanotoxicology and In Vitro Guidelines for Lanthanide‐Doped Luminescence Nanothermometers

Advanced NanoBiomed Research, EarlyView.
Lanthanide‐based luminescence nanothermometry holds multifaceted potential for nanomedical applications, yet despite significant research advances, clinical translation of the engineered nanomaterials is still controversial and widely disputed. This is related to crucial nanotoxicological aspects that must be addressed at the preclinical level ...
Simona Premcheska, Andre G. Skirtach, Anna M. Kaczmarek   +2 more
wiley   +1 more source

Kartagener’s Syndrome

Gomal Journal of Medical Sciences, 2004
Lower respiratory tract infections are a common problem in our society. In recurrent lower respiratory tract infections the cause may be either general impairment of immune mechanism, abnormalities of mucus or abnormalities of cilia.
Ihsan-ullah Mahsud, Shahab ud Din
doaj  

Clinical efficacy and tolerability of grepafloxacin in lower respiratory tract infection [PDF]

, 1998
Sanford Chodosh
openalex   +1 more source

Prospective case-control study of role of infection in patients who reconsult after initial antibiotic treatment for lower respiratory tract infection in primary care [PDF]

, 1997
J. Macfarlane, J. Prewett, D H Rose, P. Gard, Richard Cunningham, Pekka Saikku, Stephanie A. Euden, S. Myint   +7 more
openalex   +1 more source

Outcome for children under 5 years hospitalized with severe acute lower respiratory tract infections in Yemen: a 5 year experience [PDF]

, 1998
S. Banajeh
openalex   +1 more source

Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective Our objective was to evaluate the efficacy and safety of subcutaneous (SC) abatacept and standard of care (SOC) for the treatment of idiopathic inflammatory myopathy (IIM) over 52 weeks. Methods In this randomized, double‐blind, placebo‐controlled phase III trial, patients with treatment‐refractory IIM received SC abatacept (at 125 mg weekly)
Rohit Aggarwal, Ingrid E. Lundberg, Yeong‐Wook Song, Aziz Shaibani, Victoria P. Werth, Michael A. Maldonado   +5 more
wiley   +1 more source

Prevalence and Outpatient Clinical Diagnostic Approaches for Common Acute Respiratory Tract Infections in Children Under Five Years of Age: A Cross-Sectional Study

Pediatric Health, Medicine and Therapeutics
Munanura Turyasiima,1,2 Gloria Kiconco,1,3 Walufu Ivan Egesa,4 Sabinah Twesigemukama,1 Martin Nduwimana1 1Department of Pediatrics and Child Health, Kampala International University, Kampala, Uganda; 2Department of Standards Compliance Accreditation and ...
Turyasiima M, Kiconco G, Egesa WI, Twesigemukama S, Nduwimana M   +4 more
doaj  

Streamlining Antimicrobial Therapy for Lower Respiratory Tract Infections [PDF]

, 1997
Catherine M. Hitt, C H Nightingale, Richard Quintiliani, David P. Nicolau   +3 more
openalex   +1 more source

Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial

Arthritis &Rheumatology, EarlyView.
Objective An unmet need exists for glucocorticoid‐sparing treatments for patients with polymyalgia rheumatica (PMR). The antibody‐drug conjugate ABBV‐154 comprises adalimumab conjugated to a glucocorticoid receptor modulator. We evaluated ABBV‐154 versus placebo in patients with glucocorticoid‐dependent PMR.
Robert F. Spiera, Valerie Devauchelle‐Pensec, Claire E. Owen, Federico Díaz‐González, Tsutomu Takeuchi, Edit Drescher, Jaclyn Anderson, Dilek Arikan, Ronilda D'Cunha, Julie Parmentier, Denise T. Kruzikas, Weihan Zhao, Yang Yang, Karen Stellpflug, Frank Buttgereit   +14 more
wiley   +1 more source

Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis

Arthritis &Rheumatology, EarlyView.
Objective Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare, relapsing, inflammatory disease. Management of EGPA predominantly relies on oral corticosteroids (OCS), which are associated with many adverse effects. The phase 3 MIRRA trial demonstrated efficacy and safety of mepolizumab, anti‐interleukin‐5 biologic, for EGPA.
Michael E. Wechsler, Jared Silver, Gerhard Wolff, Robert G. Price, Rejina Verghis, Peter F. Weller, Peter A. Merkel, Paneez Khoury, on behalf of the EGPA Mepolizumab Open‐Label Extension study group, Arnaud Bourdin, Pascal Chanez, Anoop Chauhan, Vincent Cottin, Gerald Gleich, Berhnard Hellmich, Tomonori Ishii, David Jayne, Jean‐Emmanuel Kahn, Peter Kern, Nader Khalidi, Ina Koetter, Carol Langford, Amy Markezich, Paul Monach, Shamsa Naveed, Peter Oelzner, Kenneth Pinna, Xavier Puechal, Emory H. Robinette, Florence Roufosse, Reinhard Voll, Andrew Schafer, Kaharu Sumino, Masami Taniguchi, Phillip Lieberman   +34 more
wiley   +1 more source